(CNN) Pfizer expects to file for full US Food and Drug Administration approval for its Covid-19 vaccine for people ages 16 to 85 this month, and will seek emergency use authorization for its vaccine for children ages 2 to 11 in September, the company said during an earnings call on Tuesday.
The company’s vaccine safety and efficacy study in children age 6 months to 11 years old is still going.
“We expect to have definitive readouts and submit for an EUA for two cohorts, including children age 2-5 years of age and 5-11 years of age, in September,” Pfizer CEO Albert Bourla said, adding that the readout and submission for children 6 months to 2 years is expected in the fourth quarter of 2021.